Sandy On
6 Papers
3 Citations
Sandy On is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent
Sandy On,Carolyn Rath,Michelle Lan,Bo Wu,Kimberly M Lau,Edna Cheung,William Alegria,R. Young,Marisela Tan,Carrie Kim,Jennifer Phun,Nimish Patel,Gabriel N. Mannis,Aaron C Logan,Vanessa E Kennedy,Aaron M. Goodman,Randy Taplitz,Patricia A. Young,Raymond Y Wen,Ila M Saunders +19 more
TL;DR: An overall low risk of developing probable or confirmed IFI as well as a notable percentage of documented bacterial infections and hospital admissions due to neutropenic fever are demonstrated.
25
Neurotoxicity with blinatumomab in combination with intrathecal methotrexate therapy
Sandy On,Eric Kuo,Kimberly M Lau +2 more
TL;DR: A 26 year-old male with no significant past medical history was diagnosed with CD19, CD20, CD22, B-cell acute lymphoblastic leukemia (B-ALL) with BCR-ABL1 detected by fluorescence in situ hybridization (FISH) and 72% blasts in the bone marrow as mentioned in this paper .
3
Treatment of lymphoma with rituximab and chemotherapy during pregnancy
Sandy On,Abraham Chang +1 more
TL;DR: This review highlights the efficacy and safety of chemoimmunotherapy for mothers treated in second and third trimester for mothers with aggressive NHL treated with rituximab and concurrent chemotherapy during pregnancy.
2
Clofarabine and High-Dose Melphalan Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation
Sandy On,Walter Domingo,Edna Cheung,Laura Johnston +3 more
TL;DR: This study compares clofarabine and high-dose melphalan to fludarabine and melphalan as reduced-intensity conditioning regimens for allogeneic stem cell transplantation, finding similar efficacy outcomes but increased risk of renal failure and early mortality in patients with pre-existing kidney disease.
1
Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment.
TL;DR: Although the optimal duration of ICI therapy is unknown, this study suggests that long-term ICI use was associated with a low but notable incidence of toxicities, of which most were low in severity.